globenewswire

GAITHERSBURG, Md., June 20, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that it entered into a securities purchase agreement with an accredited investor for aggregate gross proceeds of $4.25 million, before deducting fees to the placement agent and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for potential acquisitions, marketing and other general corporate purposes.

Camfil Canada shares cost-saving air filtration tips for Ontario schools in a new article and video. Learn how advanced filters improve IAQ, cut energy expenses, and reduce maintenance needs.

The price of XRP has fluctuated violently, rising to $2.20 before falling back to about $2.15, affected by market's risk aversion. At the same time, the stablecoin RLUSD launched by Ripple was approved by Dubai, which strengthened its confidence in global expansion; a Chinese institution plans to invest $300 million in the purchase of XRP, highlighting its rising appeal. In addition, the dispute between Trump and Musk has also brought volatility to the market. XRP is still hovering around the key support level of $2.00, and the future direction depends on legal progress and ETF approval.

Definitive Agreement Signed to Acquire 80% of Smart Bridge Technology, a Profitable Agentic AI Platform

Completed in the afternoon the crossing that united the Adriatic and Tyrrhenian coasts, meeting the route of two days ago on the way down to Rome

Completata nel pomeriggio la traversata che ha unito la costa adriatica a quella tirrenica, incrociando il percorso di due giorni fa in discesa verso roma

SPRINGFIELD, N.J., June 20, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Village Super Market, Inc. (NSD-VLGEA) declared quarterly cash dividends of $0.25 per Class A common share and $0.1625 per Class B common share. The dividends will be payable on July 24, 2025 to shareholders of record at the close of business on July 3, 2025.

OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules

PRESS RELEASE

COMMUNIQUÉ DE PRESSE

Prestigious Award to Empower Aspiring Physicians Across the United States